A comparative study of the antiviral efficacy and safety of entecavir plus tenofovir versus adefovir added to continuing lamivudine in adults with lamivudine- resistant chronic hepatitis B virus infection.

Trial Profile

A comparative study of the antiviral efficacy and safety of entecavir plus tenofovir versus adefovir added to continuing lamivudine in adults with lamivudine- resistant chronic hepatitis B virus infection.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2013

At a glance

  • Drugs Adefovir dipivoxil (Primary) ; Entecavir (Primary) ; Lamivudine; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Jul 2012 Planned number of patients changed from 84 to 105 as reported by European Clinical Trials Database.
    • 25 Nov 2008 Status changed from recruiting to discontinued, as business objectives have changed, reported by ClinicalTrials.gov.
    • 28 Sep 2008 Planned end date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top